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Thefiloviruses, includingMarburg andEbola, express
a single glycoprotein on their surface, termed GP,
which is responsible for attachment and entry of
target cells. Filovirus GPs differ by up to 70% in pro-
tein sequence, and no antibodies are yet described
that cross-react among them. Here, we present the
3.6 A˚ crystal structure ofMarburg virusGP in complex
with a cross-reactive antibody fromahuman survivor,
anda lower resolution structureof theantibodybound
to Ebola virus GP. The antibody, MR78, recognizes
a GP1 epitope conserved across the filovirus fam-
ily, which likely represents the binding site of their
NPC1 receptor. Indeed, MR78 blocks binding of
the essential NPC1 domain C. These structures and
additional small-angle X-ray scattering of mucin-con-
taining MARV and EBOV GPs suggest why such
antibodies were not previously elicited in studies
of Ebola virus, and provide critical templates for
development of immunotherapeutics and inhibitors
of entry.
INTRODUCTION
The filovirus family includes Marburg virus and five ebolaviruses
(Ebola, Sudan, Reston, Bundibugyo, and Taı¨ Forest viruses),
most of which cause highly lethal hemorrhagic fever andmultiple
outbreaks among humans. Among the filoviruses, Marburg virus
was the first to be identified when it sickened laboratory workers
in Europe in 1967 (Malherbe and Strickland-Cholmley, 1968; Sie-
gert et al., 1968). Marburg virus has since re-emerged multiple
times, with modern strains conferring greater lethality (90%)
(Geisbert et al., 2007; Towner et al., 2006). Sudan virus has
caused at least six outbreaks between 1976 and 2013 (Albarin˜o
et al., 2013; Bowen et al., 1977; Sanchez and Rollin, 2005; Shoe-
maker et al., 2012), Bundibugyo virus emerged in 2007 (Towner904 Cell 160, 904–912, February 26, 2015 ª2015 Elsevier Inc.et al., 2008; Wamala et al., 2010) and again in 2012 (Albarin˜o
et al., 2013), and Reston virus was found to infect ranches of
swine being raised for human consumption in Asia in 2009 and
2011 (Barrette et al., 2009; Pan et al., 2014; Sayama et al.,
2012). Ebola virus is typically found in Central Africa, but re-
emerged inWestern Africa in 2014 to cause an outbreak unprec-
edented in magnitude and geographic spread (WHO Ebola
Response Team, 2014). During this outbreak, an experimental
Ebola virus-specific monoclonal antibody (mAb) cocktail (Qiu
et al., 2014) was used compassionately in several patients. No
such treatment yet exists that could be used against Marburg
virus or the other four ebolaviruses.
Filoviruses express a single protein on their envelope sur-
face, a glycoprotein termed GP, which is responsible for
attachment to, and entry of, host cells (Sanchez et al., 1996).
GP forms a trimer on the viral surface. In the trimer, each mono-
mer is comprised of GP1 and GP2 subunits that are anchored
together by a GP1-GP2 disulfide bond (Volchkov et al., 1998).
GP1 contains a receptor-binding core topped by a glycan
cap and a heavily glycosylated mucin-like domain (Lee et al.,
2008), while GP2 contains two heptad repeats and a transmem-
brane domain. Filoviruses initially enter cells via macropinocyto-
sis (Aleksandrowicz et al., 2011; Nanbo et al., 2010; Saeed
et al., 2010; Mulherkar et al., 2011). Once in the endosome,
the viral surface GP is cleaved by host cathepsins. Cleavage re-
moves the mucin-like domains and glycan cap (Chandran et al.,
2005; Schornberg et al., 2006; Hood et al., 2010; Marzi et al.,
2012a; Brecher et al., 2012) and renders GP competent to bind
the Niemann Pick C1 (NPC1) receptor (Carette et al., 2011;
Coˆte´ et al., 2011). Interestingly, Ebola virus entry requires cleav-
age by cathepsin B (Chandran et al., 2005; Martinez et al., 2010;
Schornberg et al., 2006), while Marburg virus entry is indepen-
dent of cathepsin B (Gnirss et al., 2012; Misasi et al., 2012).
The reasons underlying these differences are unknown. After
enzymatic cleavage and receptor binding, the GP2 subunit
unwinds from its GP1 clamp and rearranges irreversibly into a
six-helix bundle (Malashkevich et al., 1999; Weissenhorn et al.,
1998a; Weissenhorn et al., 1998b) to drive fusion of virus and
host membranes.
Antibody therapies recently have demonstrated effective
post-exposure protection against filoviruses in animal models
(Dye et al., 2012; Marzi et al., 2012b; Olinger et al., 2012; Pettitt
et al., 2013; Qiu et al., 2012; Qiu et al., 2014). MAbs can be pro-
duced on large scale and offer more reproducible effects than
polyclonal sera from survivors. However, most mAbs available
only recognize Ebola virus. Very few are yet described against
Marburg virus, and no antibodies are yet described that cross-
react among the filoviruses. Indeed, Marburg and Ebola GP
are 72% different in protein sequence, and the filoviruses are
thought to be antigenically distinct. Further, there is no structure
available for the unique Marburg virus GP, by which we may
interpret differences in requirements for viral entry, or develop
immunotherapeutics or inhibitors of entry.
Here, we report the crystal structure of the trimeric, receptor-
competent form of Marburg virus GP in complex with a neutral-
izing antibody, termed MR78, that was identified in a recent
human survivor of Marburg virus infection (Flyak et al., 2015).
Atypically, MR78 cross-reacts to cleaved Ebola virus GP. An
additional structure of MR78 in complex with Ebola virus GP
illustrates the basis of the cross-reactivity: the antibody binds
a hydrophobic ‘‘trough’’ at the top of GP1, the sequence and
structure of which are conserved across the filoviruses. We pro-
pose that this trough is the binding site of the critical domain C of
the NPC1 receptor. Indeed, MR78 blocks binding of domain C
to Marburg GP. Further, the extended third complementarity-
determining region of the heavy chain (CDR H3) of MR78 mimics
the glycan cap that shields this site on Ebola virus prior to entry
and may mimic the receptor itself. These crystal structures plus
additional biophysical analysis of complete, mucin-containing
Ebola and Marburg GP ectodomains reveal that the receptor-
binding site is masked on the surface of Ebola virus but more
exposed on the surface of Marburg virus. These findings may
explain why a cross-reactive antibody such as MR78 has not
been identified in studies of Ebola virus.
RESULTS
Structure Determination
Trimeric GP ectodomains for Marburg virus (MARV; strain
Ravn) or Ebola virus (EBOV, also known as Ebola Zaire;
strain Mayinga) were expressed in Drosophila S2 cells, with
or without their mucin-like domains (GP and GPDmuc, respec-
tively). MARV and EBOV GPDmuc were further proteolyzed
by trypsin or thermolysin, respectively, to produce cleaved
GP (GPcl) resembling the version of GP competent for receptor
binding in the endosome (Figure S1A). Three hundred versions
of MARV GP were engineered and complexed with 22 different
mAbs in order to find a crystallizable combination. Hundreds
of crystals of the final MARV GPcl-MR78 combination were
grown and screened for X-ray diffraction: just one crystal
yielded suitable diffraction.
Diffraction to 3.6 A˚ resolution was obtained from a single crys-
tal of the MARV GPcl-Fab MR78 complex. The structure was
determined by molecular replacement using EBOV GP and
Fab KZ52 (Lee et al., 2008) as search models and was refined
to Rwork of 24.7 % and Rfree of 27.9 % (Table S1). Four GP-Fab
complexes are contained in the asymmetric unit: one completetrimer and one other monomer, which forms its biologically rele-
vant trimer around a crystallographic 3-fold axis.
Differences in GP Structure between EBOV and MARV
Although the overall organization is similar betweenMarburg and
Ebola GPs (1.8 A˚ rmsd among 212 Ca atoms) (Figures 1A and
1B), several structural differences exist that may explain their
differing requirements for cellular entry. The first difference is
that the intra-GP1 disulfide bond formed by C121 and C147 in
ebolavirus GP structures (Ebola [Lee et al., 2008] and Sudan
[Bale et al., 2012; Dias et al., 2011]) does not exist in MARV. In
MARV, the two cysteines are replaced instead with L105 and
H131 (Figure 1C and Figure S1B). As a result, the equivalent
polypeptides, which form the crest of the receptor-binding sub-
unit, differ in structure and flexibility. In the ebolaviruses, the
polypeptide bearing C147 (residues 145 to 150) turns inward, to-
ward the trimer center to disulfide bond to C121. In MARV, the
equivalent polypeptide (residues 129 to 134) turns outward into
solvent, away from the trimer center.
A second difference between MARV and the ebolaviruses lies
at the base of the cathepsin cleavage loop. In MARV, these res-
idues (172-180) form a clear alpha helix (a2), which packs against
the outside of the GP2 fusion loop, interacting with both the N-
and C-terminal strands of the fusion loop (Figure 1D). In ebolavi-
ruses, the equivalent residues predict to form a loop rather than a
helix and are disordered (Bale et al., 2012; Dias et al., 2011; Lee
et al., 2008). In MARV GP, the peptide connecting this a2 helix to
b14 in the glycan cap would necessarily and immediately cover
the both N- and C-terminal arms of the GP2 fusion loop, and if
uncleaved, would hinder the conformational changes of fusion.
Structural differences in a2 of MARV may prevent effective pro-
cessing by cathepsin B.
The third difference in the MARV GP structure lies at the N ter-
minus, in the base of the b sheet that forms the GP1 spool, about
which the metastable GP2 subunit is wound. In EBOV, the base
of the spool connects to the anchoring GP1-GP2 disulfide bond
by a short stretch of polypeptide that intimately interacts with
GP2. This short connecting polypeptide contains an N-linked
glycan at Asn40, and also contains residue Asp47, which renders
EBOV dependent on cathepsin B for entry (Misasi et al., 2012). In
EBOV entry, cathepsin B removes an additional and critical
1 kDa of mass from GP beyond that removed by cathepsin L,
but the site and consequences of that extra cleavage event are
not yet known. We propose that if cathepsin B cleaves this con-
necting loop, EBOV GP2 would be freed from the constraints of
the disulfide bond and better able to undergo the conformational
rearrangements of fusion. Our crystal structure reveals that
MARV, which is cathepsin B-independent, is structured differ-
ently from EBOV at the same site. In MARV, the base of the
GP1 spool is more mobile and is shifted toward the center of
the trimer, inside of the fusion loop. Further, unlike in ebolavi-
ruses (Dias et al., 2011; Bale et al., 2012), the polypeptide
connection to the MARV GP1-GP2 disulfide could not be visual-
ized and the N-linked glycan is absent. The nearest glycan is
instead attached to residue 171 on the MARV GP1 b sheet itself
(Figure 1E). These differences in sequence, glycosylation,
mobility, and conformation likely allow MARV to be cleaved by
other enzymes and render MARV cathepsin B-independent.Cell 160, 904–912, February 26, 2015 ª2015 Elsevier Inc. 905
Figure 1. Structure of Marburg Virus GP
(A) Crystal structure of MARV GPcl (GP1, purple and GP2, dark gray) superimposed with the equivalent structure of EBOV (PDB ID, 3CSY; GP1, blue; and GP2,
light gray). The glycan cap of EBOV GP is deleted for clarity. The yellow box outlines the MR78 epitope and putative receptor-binding site. The black box outlines
the interaction site of the MARV-specific helix a2 of GP1 (purple) with the fusion loop of GP2 (dark gray). The visible N-linked sugars on MARV and EBOV GPcl
crystal structures are shown as dot models. MARV GPcl bears glycans at positions N94 and N171, which are not glycosylated in EBOV. See also Figure S1.
(B) Top view of GP.
(C) MARV GP lacks the intra-GP1 disulfide bond of EBOV. C147 of EBOV (blue) is replaced by H131 in MARV (purple), and the corresponding polypeptide traces
outward from the trimer center. The orange box outlines the glycan attachment sites at the base of each GP.
(D) Residues 172–180 of MARV form an a helix (a2) that packs against both N- and C-terminal arms of the fusion loop. In ebolaviruses, the equivalent residues are
predict to form a loop rather than a helix and are disordered in crystal structures.
(E) At the base of GP, MARV bears a glycan attached to N171 while EBOV bears a glycan attached to N40 (drawn as an oval as it was not included in the EBOV
crystal structure).Overall Organization of the MARV or EBOV GPcl Bound
to Fab MR78
The crystal structure of MARVGPcl in complex with the Fab frag-
ment of MR78 indicates that MR78 binds the membrane-distal
head of GP1 (Figure 2A). We determined an additional, low-res-
olution structure of EBOV GPcl bound to both MR78 and KZ52.
The ternary EBOV complex, determined by molecular replace-
ment, demonstrates that theMR78 antibody recognizes a similar
site on both MARV and EBOV (Figures 2B, S2, and Table S1).
MR78 binds into a highly conserved hydrophobic trough re-
vealed at the top of the EBOV GP1 core, after removal of the
glycan cap by proteolytic cleavage in the endosome. Although
MARV and EBOV diverge significantly in sequence overall, resi-
dues contained in this site, the MR78 epitope, are 85% similar
between the viruses (Figures 3A and S1B).
Likely Receptor-Binding Site
The location and structural conservation of this site suggest that
it could be the binding site of the NPC1 receptor, used by all
known filoviruses (Carette et al., 2011; Coˆte´ et al., 2011; Miller
et al., 2012; Ng et al., 2014). Indeed, in ELISA, MR78 inhibits
binding of NPC1 domain C to MARV GP (Figure S3A). This906 Cell 160, 904–912, February 26, 2015 ª2015 Elsevier Inc.site, at the apex of cleaved GP1, resembles an ocean wave
morphology, with a lower trough beneath a rising crest. The
trough is hydrophobic and is formed by a1, b4 and the loop
that connects them (residues 63-74 in MARV). It is 22 A˚ wide
and 8 A˚ deep at F72. The crest is hydrophilic, includes charged
residues previously identified as essential for virus entry (Dube
et al., 2009; Manicassamy et al., 2005; Manicassamy et al.,
2007), and is formed by strands b7, b9 and their connecting
loops (residues 92–106 and 120–134 in MARV). The 120–134
loop contains H131, which replaces the cysteine and the intra-
GP1 disulfide bond of EBOV (Figure 3B).
Here, we show by ELISA that a Q128S and N129S double
mutant in MARV GP abrogates binding to NPC1 domain C (Fig-
ure S4A). Q128 and N129 are at the tip of the crest and could
make direct hydrophilic interaction with NPC1. The trough itself
is formed by hydrophobic side chains, such as F72 (equivalent to
F88 in EBOV). Also forming the trough are the main chains of hy-
drophilic residues; these polar side chains reach away from the
trough into the trimer to make key stabilizing contacts to GP2.
Two examples are R73 and K79, previously shown to be essen-
tial for MARV infectivity (Manicassamy et al., 2007). In the crystal
structure, R73makesmultiple hydrogen bonds to the fusion loop
Figure 2. MR78Binds BothMARV andEBOV
GPcl at the Apex of GP1
(A) 3.6 A˚ crystal structure of MARV GPcl in com-
plex with Fab MR78. Each GP1 is colored a
different shade of purple, GP2 is gray, and the
MR78 Fab is in yellow.
(B) 8 A˚ structure of EBOVGPcl in complexwith Fab
MR78, determined by molecular replacement and
rigid body refinement. Each EBOV GP1 is colored
a different shade of blue and GP2 is gray. See also
Figure S2. Fab MR78 (yellow) binds the apex of
GP1 of both viruses.of the neighboring protomer in the trimer (Figure S4B) and likely
plays a key role in maintaining the prefusion structure or trans-
mitting a conformational change to the fusion loop after receptor
binding. K79 interacts with themain chain of residues 574–577 of
GP2 (Figure S4C), residues that connect the separated helical
segments of the first heptad repeat. We propose that binding
of NPC1 domain C involves contact with the hydrophilic crest
and hydrophobic trough, and that binding in the trough may
transmit conformational changes to GP2 via R73 and K79 (equiv-
alent to R89 andK95 in EBOV). AlthoughMR78 binds bothMARV
and EBOVGPcl, it only outcompetes NPC1 domain C for binding
of MARV GPcl (Figure S3B). MR78 may have lower affinity for
EBOV GPcl than MARV GPcl or domain C may bind the GPs
slightly differently.
GP-MR78 Interactions
The interaction surface between the MR78 antibody and MARV
GP buries 976 A˚2 of molecular surface and is primarily hydropho-
bic. Contact is mediated by both the heavy and light chains, but
the primary region of interaction is the 17-residue CDR H3 (Fig-
ures 3C and S3CD), which penetrates the hydrophobic trough
in MARV GP1. In this interaction, F111.2 and Y112.2 of the
CDR H3 interact with P63, S67, W70, F72, I95 and I125 of
MARV GP (IMGT numbering, Figure 4A).
Notably, these interactions are similar to those made by the
Ebola virus glycan cap, which occupies this site prior to enzy-
matic cleavage in the endosome. In Ebola virus, the equivalent in-
teractions are made by F225 and Y232 of the EBOV glycan cap
interacting with P80, T83, W86, F88, L111 and V141 on EBOV
GP (Figure 4B). Similarity may even extend to the key domain CCell 160, 904–912,of the NPC1 receptor itself, as domain C
contains similar Phenylalanine and Tyro-
sine residues that are essential for bind-
ing GP (Ndundo and Chandran, personal
communication). Further, F72 in MARV,
which is equivalent to F88 in EBOV, inter-
acts with CDR H3 in the bottom of the
trough. Both F72 of MARV and F88 of
EBOVare critical for attachment and entry
(Martinez et al., 2013; Mpanju et al., 2006)
and may interact directly with essential
hydrophobic residues of domain C. The
binding mode of MR78 is reminiscent of
anti-influenza virus human mAbs in which
longCDRH3s similarly reach into the con-served receptor-binding site (Barbey-Martin et al., 2002; Bize-
bard et al., 1995; Hong et al., 2013; Lee et al., 2014; Schmidt
et al., 2013; Whittle et al., 2011; Xu et al., 2013). In many cases
those influenza mAbs also use Phe or Tyr aromatic residues to
interact with an aromatic residue in the viral receptor binding
domain, suggesting that the favorable energetics and inter-
molecular interactions of common aromatic molecules may
constitute a canonical mode of binding of antiviral antibodies to
recessed receptor-binding sites.
Although the MR78 epitope is largely conserved in sequence
and structure between MARV and EBOV, it differs in its exposure
at different stages of virus entry. MR78 binds MARV GP equally
well whether MARV GP is in its uncleaved, viral-surface form or
its cleaved, endosomal form. In contrast,MR78 does not bind un-
cleavedEBOVGP. It onlybinds theendosomal, cleaved form from
which the glycan cap has been removed. Together, these results
suggest that in EBOV, the glycan cap effectively blocks theMR78
epitope andputative receptor-binding site on the (uncleaved) viral
surface, but that in MARV, the epitope and at least part of the
receptor-binding site is fully exposed on the viral surface. Better
exposure of this sitemay explainwhy antibodies against the puta-
tive receptor-binding site were elicited by MARV infection (see
companionpaperbyFlyaket al., 2015), but seem tobemore rarely
elicited and have not yet been described against EBOV.
Differences in Mucin-Like Domains between MARV and
EBOV, and Possible Effect on Antibody Reactivity
In addition to a glycan cap, the GP spike on the viral surface in-
cludes three heavily glycosylated mucin-like domains that are
75 kDa each in mass and are predicted to have little secondaryFebruary 26, 2015 ª2015 Elsevier Inc. 907
Figure 3. MR78 Recognizes a Conserved Epitope at the Apex of Cleaved GP1
(A) Conservation of the MR78 epitope among filovirus GPs, mapped onto one monomer of MARV GPcl. Sequence alignment was performed in ebolavirus (Ebola,
Sudan, Reston, Taı¨ Forest, Bundibugyo), marburgvirus (Musoke, Angola, Popp, Ci67, DRC1999, Ravn), and cuevavirus (Lloviu) genuses. Residues identical
across the filoviruses are colored red; residues that possess strong similarity, magenta; weak similarity, pink; no similarity, gray.
(B) The apex of cleaved MARV GP1, where Fab MR78 binds, forms a wave crest-and-trough morphology (magenta). The hydrophilic crest and the hydrophobic
trough each contain residues previously shown to be critical for virus entry (Dube et al., 2009; Manicassamy et al., 2005; Manicassamy et al., 2007; Mpanju et al.,
2006). The diagonal black line indicates the base of the trough. See also Figure S4.
(C) Surface representation of the interface between onemonomer of MARV GPcl (bottom) and FabMR78 (top). CDR H1 is colored red; CDRH2, orange; CDRH3,
purple; CDR L1, blue; CDR L2, green; CDR L3, forest green. The footprint on MARV GPcl is colored according to the CDR that mediates the contact. GP residues
contacted by MR78 are indicated and colored according to the CDR that mediates the contact (CDR names in parentheses).structure. All mucin-containing GPs thus far have been refractory
to crystallization. In order to visualize the native glycoprotein ec-
todomain and position of themucin-like domain relative to the re-
ceptor-binding core, we turned to Small-Angle X-ray Scattering
(SAXS) in solution. SAXS data collected for mucin-containing
EBOV or MARV GP trimers indicate that the mucin-like domains
of both viruses are large and extend outward from the GP core.
The radius of gyration, RG, for mucin-deleted and mucin-con-
taining MARV GPs are 50 and 72 A˚, respectively, and maximum
dimension, Dmax, for mucin-deleted and mucin-containing GPs
are 160 and 250A˚, respectively, indicating that the mucin-like
domain of MARV widens the molecule up to 90 A˚ (Figures 5A
and S5). The mucin-like domains of MARV are a bit larger than
those of EBOV (67 A˚ RG and 225 A˚ Dmax for mucin-containing
EBOV GP), consistent with their greater volume determined by
SAXS (Figure S5C) and mass noted by SDS-PAGE (Figure S5D).
Themucin-like domains of EBOV appear to project more upward
(consistent with EM tomography [Tran et al., 2014]), while
those of MARV appear to project less upward, more equatorially,
and to cover the sides of the GP trimer (Figures 5A and 5B).
Although the mucin-like domains are likely flexible (see Porod-
Debey coefficient P in Figure S5C), an equatorial, rather than
upward projection is consistent with attachment points of the
mucin-like domain to both GP1 and GP2 in MARV. In EBOV,
a different position of the furin cleavage site results in all of
mucin-like domain being attached to GP1. The MARV GP2
portion of the mucin-like domain, residues 436–509, is attached
to residue 510 on the side of the MARV GP trimer, but is flexible
and disordered.908 Cell 160, 904–912, February 26, 2015 ª2015 Elsevier Inc.A differing position of the mucin-like domains between MARV
and EBOV would leave different surfaces exposed for immune
recognition. The equatorial projection of the MARV mucin-like
domain, for example, would leave the expected receptor-bind-
ing site at the top more accessible on MARV than EBOV, and
further supports the notion that antibodies against the expected
receptor-binding site would be more likely to be elicited using
marburgvirus antigens than ebolavirus antigens. The accompa-
nying paper (Flyak et al., 2015) and other immunization studies
(Qiu et al., 2011; Wilson et al., 2000) support this notion.
In contrast, on EBOV, the upward projection of the mucin-like
domains and the absence of mucin attached to EBOV GP2
would leave the EBOV base more exposed for antibody surveil-
lance, compared to that of MARV. Indeed, in the accompanying
paper by Flyak et al., none of the 18 neutralizing antibodies
raised against MARV appear to bind the base of the MARV GP,
while multiple neutralizing antibodies elicited by ebolaviruses
are known to bind, or thought to bind, to the base of ebolavirus
GP (Dias et al., 2011; Lee et al., 2008; Qiu et al., 2012; Murin
et al., 2014) (Figure 5C).
DISCUSSION
In summary, the crystal structures and accompanying experi-
ments indicate that MR78 binds a conserved site on the apex
of GP1 that is available on the surface of MARV GP, but masked
on EBOV GP prior to enzymatic cleavage. The epitope of MR78
likely overlaps with the receptor-binding site, and hydrophobic
contacts made by CDRH3 to the hydrophobic troughmaymimic
Figure 4. Similarity in Recognition of the Pu-
tative Receptor-Binding Site by MR78 and
the Ebola Virus Glycan Cap
(A) The CDR H3 of MR78 (yellow) reaches into the
hydrophobic trough of GP1 (purple). F111.2 and
Y112.2 of CDR H3 interact with P63, S67, W70,
F72, I95, and I125 of MARV GP.
(B) Similar residues of the EBOV glycan cap (light
blue) bind into this trough on the surface of EBOV
GP (blue), prior to enzymatic cleavage. Here, F225
and Y232 of the glycan cap interact with P80, T83,
W86, F88, L111, and V141 in the trough (PDB ID;
3CSY).those of the as-yet-unvisualizedNPC1domainC.MR78 does not
neutralize authentic EBOV, likely because its epitope is masked
on the EBOV surface by the mucin-like domain and glycan cap
on the virus surface. MR78 does, however, neutralize authentic
MARV (Flyak et al., 2015) and could be a valuable monoclonal
antibody therapeutic against this extremely lethal virus. Impor-
tantly, no mAb therapeutic yet exists against MARV, and few
mAbs are yet known against MARV from which such a therapeu-
tic could be developed. The crystal structure of MARV GP pre-
sented here, and the highly conserved MR78 epitope, provide
strategies for immunotherapy and templates for development
of potentially broad-spectrum inhibitors of filovirus entry.
EXPERIMENTAL PROCEDURES
Construction, Expression, and Purification of MARV/EBOV GP
DNA encoding the MARV GPDmuc ectodomain (residues 1–636 with a mucin
deletion of residues 257–425), point mutants of MARV GPDmuc and the
EBOV GPDmuc ectodomain (residues 1–637 with a mucin deletion of residues
314–462) were amplified by PCR using codon-optimized and whole-gene syn-
thesized MARV or EBOV GPs as templates. Four point mutations in MARV
GPDmuc, F438L,W439A, F445G, and F447N, on GP2, located around the furin
cleavage site were found to improve the efficiency of furin cleavage. GP con-
structs were cloned into a derivative of the expression vector pMT. This deriva-
tivevector contains thepuromycin resistant geneandaC-terminal double-strep
tag sequence. Expression plasmids were transfected using Effectin (QIAGEN)
into 80% confluent Drosophila Schneider S2 cells. The cells were first cultured
in complete Schneider’s medium supplemented with 10% (v/v) FCS (LONZA),
and were adapted to Insect Xpress medium by progressively modifying the
Schneider/Insect Xpress medium ratio with 6.0 mg/ml puromycin. Large-scale
expression of the MARV/EBOV GPDmuc was performed using stable S2 cell
lines in 2 l Erlenmeyer flask at 27.0C, induced with 0.5 mM CuSO4. Superna-
tants containing the expressed proteins were harvested 4 days after induction,
and mixed with the Strept-Tactin affinity column binding buffer (100 mM
Tris-HCl, 150 mM NaCl, 1 mM EDTA, 15 mg/ml Avidin [pH8.0]). The proteins
were purified via Strept-Tactin affinity, followed by Superdex 200GL 10/300
(GE Healthcare Life Sciences) size-exclusion chromatography (S200 SEC).Cell 160, 904–912,Preparation and Crystallization of GP-
Antibody Complexes
To mimic endosomal protease cleavage and pro-
duce MARV GPcl, MARV GPDmuc was incubated
with 0.01 mg trypsin at 37C for 1 hr in 20 mM
TBS [pH 8.0], 100 mM NaCl. The reaction was
stopped using 0.5 mM 4-(2-Aminoethyl) benzene-
sulfonyl fluoride hydrochloride (AEBSF), and the
protein was purified by S200 SEC. EBOV GPcl
was produced by incubating EBOV GPDmuc
with 0.02 mg thermolysin overnight at room tem-perature in 20 mM TBS [pH 7.5], 100 mM NaCl, 1 mM CaCl2, and purified by
S200 SEC. Hybridoma cells expressing the human MR78 antibody were
generated from peripheral blood mononuclear cells (PBMCs) from a donor,
who contracted MARV infection in the Python Cave in Queen Elizabeth Na-
tional Park, Uganda in 2008 (see Flyak et al., 2015). MR78 was expressed in
serum-free medium (Hybridoma-SFM, GIBCO), and culture supernatants
were centrifuged, sterile-filtered, and purified over HiTrap Protein G columns
(GE Healthcare Life Sciences). Fab fragments were generated by standard
papain digestion, with released Fc and undigested IgG removed by Protein
A chromatography, and remaining Fab fragments further purified by MonoQ
ion-exchange chromatography. For crystallization, purified MARV GPcl was
mixed with excess Fab MR78 for 2 days at 4C. Complexes were separated
from unbound Fab via S200 SEC. Crystals were grown by hanging-drop va-
por diffusion at 20C using 0.8 ml protein (13.0 mg ml1, in 20 mM Tris-HCl
[pH 8.0], 100 mM NaCl) and 0.8 ml of mother liquor (100 mM NaCl, 50 mM
MES [pH 6.5], 13 % PEG 4000, 0.5 % ethyl acetate). These crystals were cry-
oprotected with 25% glycerol plus mother liquor before flash cooling in liquid
nitrogen. One crystal diffracted to a resolution of 3.6 A˚. EBOV GPcl was com-
plexed with Fabs KZ52 and MR78 and crystallized using hanging-drop vapor
diffusion at 20C with 1.0 ml of protein (6 mg/ml, 150 mM NaCl, 10 mM Tris
[pH 7.5]) and 1.0 ml of mother liquor (100 mM NaAcetate [pH 4.6], 200 mM
NH4SO4, 10% PEG 3350, 2% PEG 400). The crystals were then cryopro-
tected by washing in 100 mM NaAcetate [pH 4.6], 200 mM NH4SO4, 12%
PEG 3350, 10% PEG 400, 10% ethylene glycol. Only diffraction to 8 A˚
was obtained, but this data permitted molecular replacement using Phaser
(McCoy et al., 2007) and EBOV GP and KZ52 (Lee et al., 2008) as search
models.
ACCESSION NUMBERS
Coordinates and structure factors have been deposited into the Protein Data
Bank under the accession code 3X2D.
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Figure 5. MARV and EBOV Present Different Surfaces for Antibody Recognition
(A and B) Molecular envelopes of mucin-containing MARV and EBOV GP ectodomains determined by SAXS. Rendered Gaussian distributions of molecular
envelopes are illustrated in light gray, with ribbon models of the crystallized MARV GPcl and EBOV GPDmuc trimers to scale and overlaid for comparison. The
trimers are illustrated as ribbons. Note that the glycan cap was removed fromMARVGP used in crystallization in order to improve diffraction but was contained in
the complete MARV GP used for SAXS. The glycan cap did not inhibit diffraction of EBOV GP and is included in the EBOV GP crystal structure. MARV GPcl is
colored in purple (GP1) and gray (GP2). EBOV GPDmuc is colored blue (GP1), white blue (GP1 glycan cap), and gray (GP2). MARV GP is drawn in two possible
orientations because definitive placement of polypeptide is challenging at this resolution. In either orientation however, the mucin-like domains of MARV project
sideways, equatorially or downward from the core of GP. In MARV, the mucin-like domain is attached to both GP1 and GP2. By contrast, in EBOV, the mucin-like
domain is attached solely to GP1, there is no anchor at the base. Both these SAXS experiments and previous electron tomography (Tran et al., 2014) agree on the
upward projection of the mucin-like domains in EBOV. See also Figure S5.
(C) Differing positions of the mucin-like domains between MARV and EBOV may lead to elicitation of different types of antibodies. The lower position and GP2
anchor of the mucin-like domain of MARV may better mask the base of GP but expose its upper surfaces, allowing antibodies like mAb MR78 to be elicited. The
upward projection of the EBOV mucin-like domain and absence of any GP2 anchor, appear to better mask upper surfaces, but expose the base, allowing
antibodies such as KZ52 (Lee et al., 2008), 2G4, 4G7 (Murin et al., 2014), and 16F6 (directed against Sudan ebolavirus [Dias et al., 2011; Bale et al., 2012]) to be
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